OpenAI has launched a new advanced AI model, GPT-Rosalind, to support research into biology, drug discovery and translational medicine.
The model is built to improve scientific workflows by helping researchers analyze literature, generate hypotheses, plan experiments and connect insights across complex datasets. It focuses on early-stage discovery, where improvements can significantly affect downstream drug development timelines, which currently average 10 to 15 years in the U.S.
GPT-Rosalind is available as a research preview through ChatGPT, Codex and the API for select users. OpenAI is also launching a Life Sciences plugin for Codex that connects to more than 50 scientific tools and data sources, and is working with organizations including Amgen, Moderna and Thermo Fisher Scientific, according to an April 16 news release.
The model is named after Rosalind Franklin, whose work was foundational to understanding DNA structure.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.